

Andrea Viale

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9253751/publications.pdf>

Version: 2024-02-01

26
papers

9,682
citations

331538

21
h-index

552653

26
g-index

29
all docs

29
docs citations

29
times ranked

22848
citing authors

#	ARTICLE	IF	CITATIONS
1	Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress. <i>Cancer Research</i> , 2021, 81, 332-343.	0.4	22
2	Medium-Chain Acyl-CoA Dehydrogenase Protects Mitochondria from Lipid Peroxidation in Glioblastoma. <i>Cancer Discovery</i> , 2021, 11, 2904-2923.	7.7	23
3	miR-9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC. <i>EMBO Molecular Medicine</i> , 2021, 13, e12872.	3.3	15
4	PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. <i>Nature Communications</i> , 2021, 12, 4626.	5.8	31
5	Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. <i>Gastroenterology</i> , 2021, 161, 196-210.	0.6	23
6	Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. <i>Science</i> , 2021, 373, eabj0486.	6.0	99
7	Leukotrienes, a potential target for Covid-19. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2020, 161, 102174.	1.0	12
8	The Many Facets of Tumor Heterogeneity: Is Metabolism Lagging Behind?. <i>Cancers</i> , 2019, 11, 1574.	1.7	28
9	Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors. <i>Cell Reports</i> , 2019, 26, 1518-1532.e9.	2.9	70
10	Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. <i>Nature</i> , 2019, 568, 410-414.	13.7	129
11	p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. <i>Cancer Cell</i> , 2019, 35, 204-220.e9.	7.7	62
12	Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. <i>Nature</i> , 2017, 542, 119-123.	13.7	209
13	Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. <i>Nature</i> , 2017, 542, 362-366.	13.7	105
14	Metabolic Features of Cancer Treatment Resistance. <i>Recent Results in Cancer Research</i> , 2016, 207, 135-156.	1.8	34
15	In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. <i>Cell Reports</i> , 2016, 16, 133-147.	2.9	114
16	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
17	Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome. <i>Cancer Cell</i> , 2015, 27, 644-657.	7.7	85
18	Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer. <i>Cancer Research</i> , 2015, 75, 1091-1101.	0.4	68

#	ARTICLE	IF	CITATIONS
19	Sugar? No Thank You, Just a Deep Breath of Oxygen for Cancer Stem Cells. <i>Cell Metabolism</i> , 2015, 22, 543-545.	7.2	9
20	Tumors and Mitochondrial Respiration: A Neglected Connection. <i>Cancer Research</i> , 2015, 75, 3687-3691.	0.4	204
21	Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. <i>Nature</i> , 2014, 514, 628-632.	13.7	998
22	Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer. <i>Cell</i> , 2014, 158, 185-197.	13.5	553
23	DNA damage in stem cells activates p21, inhibits p53, and induces symmetric self-renewing divisions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 3931-3936.	3.3	123
24	Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism. <i>Cell</i> , 2012, 149, 656-670.	13.5	1,587
25	Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. <i>Nature</i> , 2009, 457, 51-56.	13.7	289
26	Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. <i>Blood</i> , 2002, 100, 4391-4400.	0.6	84